Vifor Pharma Group is hopeful that its hyperkalemia therapy Veltassa, which enjoyed strong sales growth in 2019, will be able to fend off competition from AstraZeneca PLC's rival treatment Lokelma.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?